Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
Can mixed results gain an expansion for Karyopharm's Xpovio?
Karyopharm has provided mixed results from a phase 3 trial testing Xpovio in combination with Incyte's Jakafi in patients with myelofibrosis.
Kevin Dunleavy
Mar 24, 2026 11:56am
Legend sloughs off Carvykti threat from J&J's Tecvayli
Mar 12, 2026 2:00pm
Tecvayli-Darzalex combo earns national priority nod from FDA
Mar 6, 2026 8:00am
Quadruplet Darzalex regimen bags new myeloma nod
Jan 28, 2026 8:55am
Johnson & Johnson's Tecvayli struts its stuff as a monotherapy
Jan 15, 2026 10:15am
FDA 'proactively' awards J&J a national priority review voucher
Dec 15, 2025 12:33pm
